Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 9Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Condylomata Acuminata 1

Interventions

Paclitaxel 79Carboplatin 66pembrolizumab 61Bevacizumab 56Cisplatin 48Specimen Handling 29Drug Therapy 26Blood Specimen Collection 24Cyclophosphamide 20olaparib 19Taxes 17Magnetic Resonance Spectroscopy 16Letrozole 16Gemcitabine 16Biopsy 16liposomal doxorubicin 15niraparib 14fludarabine 14Brachytherapy 14Radiotherapy 13abemaciclib 12Topotecan 11Nivolumab 11Injections 11Doxorubicin 11lenvatinib 10Fluorouracil 10atezolizumab 9Surveys and Questionnaires 9Standard of Care 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Vaccines, Synthetic × Gynecologic × Clear all
NCT04422366 2024-06-07

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Shanghai Bovax Biotechnology Co., Ltd.

Phase 3 Recruiting
8,000 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡